One qualified iPSC bank can support large numbers of doses. That is the platform advantage, and it a...
Insights
By the time an iPSC-derived product reaches release testing, most of what determines its quality was...
For short-life ATMPs, sterility is assured throughout the entire manufacturing process, not by a sin...
Rethinking CAR-T Manufacturing: A Single-Step Path to Lower COGS and Higher Yield Autologous CAR-T t...
Designing an operational model for autologous T cell manufacturing is only the starting point. Execu...
From process design to patient delivery, success depends on how the manufacturing system operates un...
From activation through gene modification and expansion, small development decisions often determine...
The decision to build in-house or partner with a CDMO is less philosophical than it appears. At its ...
Cell therapy involves the transfer of living cells into a patient to treat, cure, or prevent disease...
When mesenchymal stem cells (MSCs) behave, they are remarkably manufacturable. When they do not, the...